Glucocorticoids Mediate Drug Resistance: Mechanisms And Its Clinical Impact

Weimin Fan,Meihua Sui

2011-01-01

Abstract:Drug resistance is one of the major obstacles limiting the success of cancer chemotherapy. Biological mechanisms contributing to drug resistance may be present de novo and relate to inherent cellular features or may arise after exposure to anticancer drugs. In this field, the most widely studied phenomenon is multidrug resistance (MDR) that has been linked to overexpression of a membrane associated P-glycoprotein (P-gp). In recent years, both clinical observations and experimental studies suggested that steroid hormones and their receptors might also affect the therapeutic efficacy of antineoplastic drugs. This article will introduce the latest research progresses on the discovery and characterization of the drug resistance mediated by glucocoticoids.Glucoroticoids are essential steroid hormones required for the maintenance of many physiological and developmental processes. Glucocorticoids such as dexamethasone are widely used as premedication to prevent the side or adverse effects of many chemotherapeutic agents such as paclitaxel and docetaxel. Recent studies in our laboratory and others discovered that glucocorticoids could selectively inhibit paclitaxel-induced apoptosis in vitro. Through development of animal models bearing human breast and ovarian xenograft tumors, we demonstrated that pretreatment of dexamethasone significantly attenuated the therapeutic efficacy of paclitaxel in vivo. Further investigation indicate that glucocorticoids have little influence on the ability of paclitaxel to induce microtubule bundling and mitotic arrest, but specifically block apoptotic cell death by antagonizing the regulatory effect of paclitaxel on activation of NF-kappa B/I kappa B signaling pathway. Since glucocorticoids are routinely used in the clinical application of paclitaxel to prevent hypersensitivity reactions and other adverse effects, the inhibitory action of glucocorticoids on paclitaxel-induced apoptosis also raises a clinically relevant question as to whether the pretreatment with glucocorticoids might interfere with the therapeutic efficacy of paclitaxel and possibly other chemotherapeutic agents.